PARDES BIOSCIENCES

Summary

Pardes Biosciences is an operator of a pre-clinical stage biotechnology company committed to solving a few of the health challenges faced by the masses.

Deals Overview

Total Deals2

Valued Deals2

Total Value£ 295 M

Avg. Deal Size£ 148 M

Market Context

Senior Management

Uri A. Lopatin
CEO
Heidi Henson
CFO
Elizabeth Lacy
General Counsel

Sort

29 Jun 2021|United States|Biotechnology

Target: PARDES BIOSCIENCES

Bidder: ECOR1 CAPITAL

17 Service Providers

4 Target | 13 Bidder

37 Dealmakers

9 Target | 29 Bidder

£ 199 M

Value

17 Jul 2023|United States|Biotechnology

Target: PARDES BIOSCIENCES

Bidder: MEDIPACIFIC INC

3 Service Providers

2 Target | 1 Bidder

27 Dealmakers

14 Target | 13 Bidder

£ 95 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy